-+ 0.00%
-+ 0.00%
-+ 0.00%

ENVEDA ANNOUNCES US FDA IND CLEARANCE AND FIRST PATIENT DOSED IN PHASE 1 TRIAL OF ENV-308, A FIRST-IN-CLASS ORAL THERAPY FOR OBESITY

Reuters·12/17/2025 13:01:34

Please log in to view news